A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to use 24 week survival to assess the efficacy of the
combination of Gliadel followed by Avastin and irinotecan in the treatment of grade IV
malignant glioma patients following surgical resection. The secondary objectives are to
determine the progression-free survival following the combination of Gliadel followed by
Avastin and irinotecan and to describe the toxicity of Gliadel followed by Avastin and
irinotecan.